Figure 2

Preincubation of sera from CSU patients with OmAb does not modify the ability of the sera to stimulate mast cells. (A) Brief scheme of the experimental protocol used in (B and C). (B) LAD2 cells were incubated with sera samples from CSU patients who were pre-incubated with different doses of OmAb, or hIgG as a control, for 30 min. The bar charts represent the percentage of the mean fluorescence intensity (MFI) of CD63 staining relative to that in OmAb/IgG untreated cells (first bar). (C) Basophils from healthy donors were incubated with sera samples from CSU patients who were pre-incubated with different doses of OmAb, or hIgG as a control, for 30 min. The bar charts represent the percentage of the MFI of CD63 staining relative to that in OmAb/IgG untreated cells (first bar). (D) Brief scheme of the experimental protocol used in (E). (E) IgE^B was incubated with different doses of OmAb, or IgG as a control, for 30 min. Then, LAD2 cells were incubated overnight with this mixture, and cells were stained for CD63 after IgE^B challenge. The bar charts represent the percentage of the MFI of CD63 staining relative to that in OmAb/IgG untreated cells (first bar).